Scientists crack how aspirin might stop cancers from spreading
Scientists believe they have discovered how the cheap painkiller aspirin can stop cancers spreading.
In animal experiments they showed the drug enhanced the ability of the immune system to fight back.
The team at the University of Cambridge said it was an exciting and surprise discovery that could eventually lead to cancer patients being prescribed the drug - but not yet and people are advised against just taking the pills themselves.
Regular aspirin comes with risks and trials are still trying to figure out which patients are most likely to benefit.
Tantalising data from more than a decade ago showed people who were already taking a daily aspirin were more likely to survive if they were diagnosed with cancer.
But how?
It appears to centre on a moment of vulnerability for a cancer - when a lone cell breaks off from the original tumour and tries, like a seed on the wind, to spread elsewhere in the body.
This process is called metastasis and is the cause of the majority of deaths from cancer.
Part of our immune defences - a white blood cell called a T-cell - can swoop in and destroy the spreading cancer as it tries to take root.
But the study showed that another part of our blood - the platelets that normally stop bleeding - were suppressing the T-cells and making it harder for them to take out the cancer.
Aspirin disrupts the platelets and removes their influence over the T-cells so they can hunt out the cancer.
Prof Rahul Roychoudhuri, from the University of Cambridge, told me: "What we've discovered is that aspirin might work, surprisingly, by unleashing the power of the immune system to recognize and kill metastasizing cancer cells."
He thinks the drug would work best in cancers that have been caught early and could be used after treatment such as surgery to help the immune system find any cancer that might already have spread.
The most natural question for anybody with cancer to ask is should they be taking aspirin.
"If you are a cancer patient, don't rush to your local pharmacy to buy aspirin just yet, but actively consider participation in ongoing or upcoming trials of aspirin," says Prof Mangesh Thorat, a surgeon and cancer researcher at Queen Mary University of London.
He says the study provided "the missing piece of the jigsaw puzzle" in understanding how aspirin works, but there were still questions to answer.
Aspirin can cause dangerous internal bleeding including strokes so the risks have to be balanced. It is also not clear whether the effect works for all cancer or just specific ones. And this is still animal research so while the scientists think this would apply in people that will still need to be confirmed.
Some patients - with Lynch syndrome, which increases the risk of cancers - are already recommended aspirin.
But it will still take proper clinical trials to understand whether more patients would benefit too.
These are already under way. Prof Ruth Langley, from the MRC Clinical Trials Unit at University College London, is leading the Add-Aspirin trial to see if aspirin can stop early stage cancers from coming back.
She said the study's results were "an important discovery" as they would help to work out "who is most likely to benefit from aspirin after a cancer diagnosis".
However, she again warned of the risks of taking aspirin and to "always talk to your doctor before starting".
In the long-run, Prof Roychoudhuri suspects new drugs would be developed that take the benefits of aspirin, but with fewer of the risky side-effects.
The discovery, published in the journal Nature, happened by accident as the scientists were not researching aspirin.
The team in Cambridge were investigating how the immune system responded to cancers when they spread.
They were using genetically engineered mice and found those lacking a specific set of genetic instructions were less likely to get metastatic cancer that had spread.
Further investigation revealed how those T-cells were being suppressed and this started to overlap with how aspirin was known to work in the body.
Dr Jie Yang, who carried out the research, said: "It was a Eureka moment.
"It was an entirely unexpected finding which sent us down quite a different path of inquiry than we had anticipated."
Boots recalls paracetamol over labelling error
Warning over rapid at-home prostate tests
Aspirin 'may prevent cancer in diabetes patients'
Cancer family 'financially broken' by benefits wait
Brain surgery took my childhood memories - will new op make me forget my fiance?
The ultra-fast cancer treatments which could replace conventional radiotherapy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Animals Expend 76,000 Gigajoules of Energy Sculpting Our Planet Every Year
Earth's surface is a work forever in progress. Boulders tumble down mountain slopes raised by colliding tectonic plates. Glaciers grind the boulders into dust. Wind, rain and rivers carry that dust to the sea, where it becomes sediment. These are among the traditional ways landscapes are known to change. But new research suggests there's a mighty force of nature missing from this picture: animals. In a study published in the Proceedings of the National Academy of Sciences USA, researchers estimate that wild freshwater and terrestrial species, ranging from salmon to elephants, expend 76,000 gigajoules of energy to alter the land around them every year—the equivalent of thousands of extreme floods. Beavers are, of course, famous for their engineering feats. But when it comes to other animals, no matter how extensive their nest building or den digging is, 'the perception has been that they're interesting curiosities but really not that important globally,' says the study's lead author, Gemma L. Harvey, a physical geographer at Queen Mary University of London. 'This paper challenges that.' [Sign up for Today in Science, a free daily newsletter] The study of landform evolution is called geomorphology, and when the changes are caused by animals, we tack on another prefix: zoogeomorphology. As early as 1881, Charles Darwin recognized earthworms' role in soil formation. But it wasn't until 1992 that physical geographer David Butler, now a professor emeritus at Texas State University, coined the term for the effect. He debuted this scientific mouthful that year in a paper on 'the grizzly bear as an erosional agent,' in which he calculated that the bears in Glacier National Park had, over the course of 100 years, moved about 15,000 dump-truck loads of dirt downslope while foraging for food and excavating their dens. 'It made me suspect that if you did this worldwide for hundreds of species, you would come up with astonishing numbers,' he says. The data needed for this kind of investigation weren't available then, but three decades later Harvey's team found enough to analyze 500 species. The researchers learned that trampling hippos create entirely new river channels, and burrowing crayfish widen the banks of existing ones. They found that hulking termite mounds cover an Iceland-size patch of Brazil. 'Those are huge areas,' Harvey says, 'huge amounts of soil being transformed.' Brian Yanites, a geomorphologist at Indiana University Bloomington, who was not involved in this study, notes that such research is often hyperlocalized to 'one type of animal, one specific location or particular landform.' But he says the new work 'is a really elegant way to approach the problem from a macro level.' If anything, the authors think 76,000 gigajoules is probably a wild underestimate; they excluded vast biodiversity hotspots in Africa, South America and Asia because there are few published studies on how living creatures reshape lands in those regions. Although many experts disregard animals as a source of profound landscape change, Butler says, 'I think this study could be a 'Holy crap!' moment for them.'
Newsweek
3 days ago
- Newsweek
Long-Term Use of This Contraceptive Pill Linked to Increased Brain Tumor Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Using the progestogen-only contractive pill "desogestrel" for more than five years may increase the risk of developing a type of brain tumor known as an "intracranial meningioma," a new study has warned. The researchers noted that the risk is low—and is eliminated one year after desogestrel treatment is suspended—but that doctors' awareness of the possibility could eliminate the need for surgery in some cases. Meningiomas are a rare, non-cancerous form of tumor that arise from the membranes surrounding the brain. While slow-growing and benign in and of themselves, they can develop to a size that compresses other structures in the brain. They usually only require surgery when they cause symptoms such as persistent headaches or neurological issues. Woman holding combined oral contraceptive pill. Woman holding combined oral contraceptive pill. PATCHARIN SIMALHEK The study, based on data from France's national health system, compared over 8,000 women who underwent surgery for meningioma between 2020 and 2023 with more than 83,000 matched controls. Researchers found that women who had taken desogestrel continuously for more than five years had a slightly elevated risk of developing the brain tumors. Reassuringly, no increased risk was found for short-term use or for other commonly used progestogens like levonorgestrel, either alone or combined with estrogen. "This large study using French national database... shows [an] association between taking a certain progestogen (desogestrel) continuously for more than five years and meningioma risk, however, the magnitude of increase in the risk is small," said paper author Dr. Mangesh Thorat of Queen Mary University of London in a statement. Short-term use does not increase risk and the risk ceases after stopping use, he added. The authors estimate that one woman in every 67,000 using desogestrel would need surgery for meningioma and this drops to 1 in 17,000 with continuous use beyond five years. By comparison, breast cancer is about 10 times more common than meningioma. To understand progestogens, Thorat said it's crucial to note that the effects of different drug formulations can vary significantly and individual drugs can affect various organs differently. "Therefore, it is important to consider which specific drug is being used by an individual," he said. The study also showed that Microgynon and the morning-after pill—both containing levonorgestrel—were not linked to increased risk. Still, the findings have clinical relevance, especially for women over 45 or those with a prior history of using other high-risk progestogens. In such cases, the study suggests discontinuing desogestrel if a meningioma is identified, rather than jumping straight to surgery. "Stopping desogestrel may also avoid unnecessary potentially harmful treatments," said neurosurgeon Gilles Reuter of the University Hospital Liegein an accompanying editorial. Reuter emphasized that similar results have already been seen with other high-risk progestogens. While the study is observational and cannot prove cause and effect, its large sample size adds weight to the findings. However, experts say the takeaway should be caution, not alarm. For those affected by the findings, Thorat advises speaking with a healthcare provider regarding which drug is being used. "If it is associated with an increased risk of meningioma, this can be changed to a safer alternative," he said. "There is no reason to panic as the risk is very small and even in those who developed meningioma, stopping the specific drug has shown to cause regression in the size of meningioma." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about contraceptives? Let us know via health@ References Roland, N., Kolla, E., Baricault, B., Dayani, P., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2025). Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: National case-control study. BMJ, 389. Reuter, G. (2025). Progestogens and meningioma: New evidence on levonorgestrel and desogestrel. BMJ, 389.
Miami Herald
3 days ago
- Miami Herald
New synthetic ‘skin' gives robots human touch
By Stephen Beech A new synthetic "skin" gives robots the human touch. The low-cost, durable and highly-sensitive material can be added to robotic hands just like a glove, say scientists. It enables automatons to detect information about their surroundings in a way that's similar to humans, according to research published in the journal Science Robotics. The research team, from the University of Cambridge and University College London (UCL), developed the flexible, conductive skin, which is easy to fabricate and can be melted down and formed into multiple shapes. They say the new technology senses and processes various physical inputs, allowing robots to interact with the physical world in a more meaningful way. Unlike other solutions for robotic touch, which usually work via sensors embedded in small areas and require different sensors to detect different types of touch, the entirety of the electronic skin developed by the British team is a sensor, bringing it closer to human skin. Previously, signals from different sensors could interfere with each other, and the materials were easily damaged. Although the new robotic skin is not as sensitive as human skin, the researchers say it can detect signals from more than 860,000 tiny pathways in the material. That enables it to recognise different types of touch and pressure, such as the tap of a finger, a hot or cold surface, damage caused by cutting or stabbing, or multiple points being touched at once, in a single material. The research team used a combination of physical tests and machine learning techniques to help the robotic skin "learn" which of these pathways matter most, so it can sense different types of contact more efficiently. As well as the potential for humanoid robots or human prosthetics where a sense of touch is vital, the researchers say the robotic skin could be useful in industry and even disaster relief. Study lead author Dr. David Hardman, from Cambridge's Department of Engineering, said: "Having different sensors for different types of touch leads to materials that are complex to make. "We wanted to develop a solution that can detect multiple types of touch at once, but in a single material." Co-author Dr. Thomas George Thuruthel, of UCL, said: "At the same time, we need something that's cheap and durable, so that it's suitable for widespread use." Their solution uses a type of sensor that reacts differently to different types of touch, known as multi-modal sensing. While it's challenging to separate out the cause of each signal, the researchers explained that multi-modal sensing materials are easier to make and more robust. The team melted down a soft, stretchy and electrically conductive gelatine-based hydrogel, and cast it into the shape of a human hand. They tested several different electrode configurations to determine which gave them the most useful information about different types of touch. From 32 electrodes placed at the wrist, they were able to collect more than 1.7 million pieces of information over the whole hand, thanks to the tiny pathways in the conductive material. The skin was then tested on different types of touch. The researchers blasted it with a heat gun, pressed it with their fingers and a robotic arm, gently touched it with their fingers, and even cut it open with a scalpel. They then used the data gathered during testing to train a machine learning model so the hand would recognise what the different types of touch meant. Dr. Hardman said: "We're able to squeeze a lot of information from these materials – they can take thousands of measurements very quickly. "They're measuring lots of different things at once, over a large surface area." Dr. Thuruthel added: "We're not quite at the level where the robotic skin is as good as human skin, but we think it's better than anything else out there at the moment. "Our method is flexible and easier to build than traditional sensors, and we're able to calibrate it using human touch for a range of tasks." The team is now hoping to improve the durability of the electronic skin and to carry out further tests involving real-world robotic tasks. The post New synthetic 'skin' gives robots human touch appeared first on Talker. Copyright Talker News. All Rights Reserved.
